Description: Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company's approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Indaptus' patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, with reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. This approach has led to broad anti-tumor and anti-viral activity, including safe, durable anti-tumor response synergy with each of five different classes of existing agents, including checkpoint therapy, targeted antibody therapy and low-dose chemotherapy in pre-clinical models. Tumor eradication by Indaptus technology has demonstrated activation of both innate and adaptive immunological memory and, importantly, does not require provision of or targeting a tumor antigen in pre-clinical models. Indaptus has carried out successful GMP manufacturing of its lead clinical candidate, Decoy20, and is currently completing other IND-enabling studies.
Home Page: indaptusrx.com
INDP Technical Analysis
3 Columbus Circle
New York,
NY
10019
United States
Phone:
347 480 9760
Officers
| Name | Title |
|---|---|
| Mr. Jeffrey A. Meckler | CEO & Director |
| Dr. Michael J. Newman Ph.D. | Founder, Chief Scientific Officer & Director |
| Mr. Walt Addison Linscott Esq. | Chief Bus. Officer |
| Mr. Nir Sassi | CFO, Sec. & Treasurer |
| Dr. Boyan Vesselinov Litchev M.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5213 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2015-08-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |